Study on human GPCR-inhibitor interactions by proteochemometric modeling

Gene

Volumn 518, Issue 1, 2013, Pages 124-131

  Gao, Jun ^a,b   Huang, Qi ^a   Wu, Dingfeng ^a   Zhang, Qingchen ^a   Zhang, Yida ^a   Chen, Tian ^a   Liu, Qi ^a   Zhu, Ruixin ^a   Cao, Zhiwei ^a   He, Yuan ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI MARITIME UNIVERSITY   (China)

Author keywords

Cross interaction; G protein coupled receptor; Proteochemometric; Systematic study

Indexed keywords

G PROTEIN COUPLED RECEPTOR INHIBITOR; LIGAND; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; KERNEL METHOD; MEMBRANE POTENTIAL; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEOCHEMOMETRIC MODEL; RECEIVER OPERATING CHARACTERISTIC; SIGNAL TRANSDUCTION; SUPPORT VECTOR MACHINE;

CLOZAPINE; DRUG DESIGN; HUMANS; LIGANDS; MODELS, CHEMICAL; RECEPTORS, G-PROTEIN-COUPLED; REPRODUCIBILITY OF RESULTS; RISPERIDONE; ROC CURVE;

EID: 84875379096     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.11.061     Document Type: Article

References (41)

1. Baldwin J.M., Schertler G.F.X., Unger V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272:144-164.
2. Bunin B. Collaborative Drug Discovery (CDD) pp. https://www.collaborativedrug.com/.
3. Devi L.A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol. Sci. 2001, 22:532-537.
4. DrugBank, DB00363 Clozapine pp. http://www.drugbank.ca/drugs/DB00363.
5. DrugBank, DB00734 Risperidone pp. http://www.drugbank.ca/drugs/DB00734.
6. EMBL-EBI GPCR SARfari version 2.0 pp. https://www.ebi.ac.uk/chembl/sarfari/gpcrsarfari.
7. Fernandez M., Ahmad S., Sarai A. Proteochemometric recognition of stable kinase inhibition complexes using topological autocorrelation and support vector machines. J. Chem. Inf. Model. 2010, 50:1179-1188.
8. Filmore D. It's a GPCR world. Mod. Drug Discovery 2004, 7:24-28.
9. Freyhult E., Prusis P., Lapinsh M., Wikberg J.E., Moulton V., Gustafsson M.G. Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling. BMC Bioinforma. 2005, 6.
10. Howard A.D., et al. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 2001, 22:132-140.
11. Huang D., et al. Comparison of ligand-, target structure-, and protein-ligand interaction fingerprint-based virtual screening methods. Acta Chim. Sinica 2011, 69:515-522.
12. Huang Q., et al. Proteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprint. PLoS One 2012, 7:e41698.
13. Insel P.A., Tang C.M., Hahntow I., Michel M.C. Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim. Biophys. Acta 2007, 1768:994-1005.
14. Kang H., Sheng Z., Zhu R., Huang Q., Liu Q., Cao Z. Virtual drug screen schema based on multiview similarity integration and ranking aggregation. J. Chem. Inf. Model. 2012, 52:834-843.
15. Labute P. A widely applicable set of descriptors. J. Mol. Graph. Model. 2000, 18:464-477.
16. Lapins M., Wikberg J.E.S. Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. BMC Bioinforma. 2010, 11.
17. Lapinsh M., Prusis P., Gutcaits A., Lundstedt T., Wikberg J.E.S. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Biochim. Biophys. Acta, Gen. Subj. 2001, 1525:180-190.
18. Lapinsh M., Prusis P., Lundstedt T., Wikberg J.E.S. Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol. Pharmacol. 2002, 61:1465-1475.
19. Lapinsh M., Prusis P., Mutule I., Mutulis F., Wikberg J.E.S. QSAR and proteo-chemometric analysis of the interaction of a series of organic compounds with melanocortin receptor subtypes. J. Med. Chem. 2003, 46:2572-2579.
20. Lapinsh M., Prusis P., Uhlen S., Wikberg J.E.S. Improved approach for proteochemometrics modeling: application to organic compound-amine G protein-coupled receptor interactions. Bioinformatics 2005, 21:4289-4296.
21. Lapinsh M., et al. Proteochemometric mapping of the interaction of organic compounds with melanocortin receptor subtypes. Mol. Pharmacol. 2005, 67:50-59.
22. Liu Q., Che D.S., Huang Q., Cao Z.W., Zhu R.X. Multi-target QSAR study in the analysis and design of HIV-1 inhibitors. Chin. J. Chem. 2010, 28:1587-1592.
23. Liu Q., Zhou H., Liu L., Chen X., Zhu R.X., Cao Z.W. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study. BMC Bioinforma. 2011, 12.
24. Lutu P.E.N., Engelbrecht A.P. Using OVA modeling to improve classification performance for large datasets. Expert Syst. Appl. 2012, 39:4358-4376.
25. Ma C., Kang H., Liu Q., Zhu R.X., Cao Z.W. Insight into potential toxicity mechanisms of melamine: an in silico study. Toxicology 2011, 283:96-100.
26. Prusis P., Muceniece R., Andersson P., Post C., Lundstedt T., Wikberg J.E.S. PLS modeling of chimeric MS04/MSH-peptide and MC1/MC3-receptor interactions reveals a novel method for the analysis of ligand-receptor interactions. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 2001, 1544:350-357.
27. Prusis P., Lundstedt T., Wikberg J.E.S. Proteo-chemometrics analysis of MSH peptide binding to melanocortin receptors. Protein Eng. 2002, 15:305-311.
28. Rasmussen C.E., Williams C.K.I. Gaussian Processes for Machine Learning 2006, The MIT Press, London, England.
29. RxList Risperdal (Risperidone) Drug - Clinical Pharmacology http://www.rxlist.com/risperdal-drug/clinical-pharmacology.htm.
30. Sandberg M., Eriksson L., Jonsson J., Sjostrom M., Wold S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J. Med. Chem. 1998, 41:2481-2491.
31. Schioth H.B., Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol. 2005, 142:94-101.
32. Seal A., Aykkal R., Babu R.O., Ghosh M. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 2011, 5:430-439.
33. Sodhi A., Montaner S., Gutkind J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. Nat. Rev. Mol. Cell Biol. 2004, 5:998-1012.
34. Suwa M., Sugihara M., Ono Y. Functional and structural overview of G-protein-coupled receptors comprehensively obtained from genome sequences. Pharmaceuticals 2011, 4:652-664.
35. van Westen G.J.P., Wegner J.K., Ijzerman A.P., van Vlijmen H.W.T., Bender A. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. Medchemcomm 2011, 2:16-30.
36. Vroling B., et al. GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res. 2011, 39:D309-D319.
37. Wise A., Gearing K., Rees S. Target validation of G-protein coupled receptors. Drug Discov. Today 2002, 7:235-246.
38. Xu J., Stevenson J. Drug-like index: a new approach to measure drug-like compounds and their diversity. J. Chem. Inf. Comput. Sci. 2000, 40:1177-1187.
39. Yanamala N., Gardner E., Riciutti A., Klein-Seetharaman J. The cytoplasmic rhodopsin-protein interface: potential for drug discovery. Curr. Drug Targets 2012, 13:3-14.
40. Zhu R.X., Liu Q., Tang J., Li H.L., Cao Z.W. Investigations on inhibitors of hedgehog signal pathway: a quantitative structure-activity relationship study. Int. J. Mol. Sci. 2011, 12:3018-3033.
41. Zhu R.X., Wang F., Liu Q., Kang T.G. Quantitative structure-activity relationship of IOPY/ISPY analogues as HIV-1 non-nucleoside reverse transcriptase inhibitors. Acta Chim. Sinica 2011, 69:1731-1736.